NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.

By
Andrea Surnit
June 4, 2026
6 min

MDSpire News

Objective:

To evaluate the impact of participation in the NHS-Galleri trial on diagnostic delay rates for suspected head and neck, lung, and upper gastrointestinal cancers.

Key Findings:

Diagnostic delay rates increased from 29% to 30% in participating regions and decreased from 29% to 26% in nonparticipating regions during the first 6 months.
Participation in the trial was associated with an approximately 3-percentage-point increase in diagnostic delay rates.
The estimated increase in delayed referrals during the first year was 9,591.
Average time to diagnostic resolution increased by about 2 days in participating regions.

Interpretation:

Limitations:

Participating regions had greater socioeconomic deprivation and fewer healthcare staff than nonparticipating regions, raising the possibility of residual confounding.
Only 6 months of pretrial data were available to assess baseline trends.
The data could not distinguish between referrals that resulted in cancer diagnosis and those in which cancer was ruled out.

NHS-Galleri Linked to Delays

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

NHS-Galleri Linked to Delays

Related Content

Trends in alcohol-linked cancer mortality

FDA approves first therapy for warm autoimmune hemolytic anemia

FDA raises TMB threshold for pembrolizumab